Ascendis Pharma (ASND) earnings
Ascendis Pharma (ASND) reported net income of -€228.03M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -€378.08M. Figures as of 18 Nov 2026, 01:59 UTC, from Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- -€228.03M
- Highest on record
- -€228.03Mfiscal 2025
- Lowest on record
- -€583.19Mfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in EUR. Figures, not advice.
Ascendis Pharma earnings, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was -€228.03M in fiscal 2025 and the lowest -€583.19M in fiscal 2022.
Earnings (net income) by fiscal year
Ascendis Pharma earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | -€228.03M | — | |
| 2024 | -€378.08M | — | |
| 2023 | -€481.45M | — | |
| 2022 | -€583.19M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Earnings (net income) at health care companies of similar size
| Company | Earnings (net income) | Fiscal year |
|---|---|---|
| Revvity RVTY | $241.20M | 2025 |
| Exelixis EXEL | $782.57M | 2025 |
| Charles River Laboratories International CRL | -$144.34M | 2025 |
| Neurocrine Biosciences NBIX | $478.60M | 2025 |
| Ascendis Pharma ASND | -€228.03M | 2025 |
| ICON ICLR | $229.34M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Ascendis Pharma, figure by figure
- Ascendis Pharma market cap
- Ascendis Pharma revenue
- Ascendis Pharma earnings per share (EPS)
- Ascendis Pharma P/E ratio
- Ascendis Pharma P/S ratio
- Ascendis Pharma P/B ratio
- Ascendis Pharma free cash flow
- Ascendis Pharma operating margin
- Ascendis Pharma dividend
- Ascendis Pharma shares outstanding
- Ascendis Pharma total debt
- Ascendis Pharma cash on hand
- Ascendis Pharma total assets
- Ascendis Pharma return on equity (ROE)
- Ascendis Pharma return on invested capital (ROIC)
Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value
Ascendis Pharma earnings: questions and answers
What is Ascendis Pharma's net income?
Ascendis Pharma (ASND) reported net income of -€228.03M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -€378.08M.
What are the highest and lowest net income figures on record for Ascendis Pharma?
Across the 4 fiscal years on record (2022–2025), the highest was -€228.03M in fiscal 2025 and the lowest -€583.19M in fiscal 2022.
How is Ascendis Pharma's net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Ascendis Pharma (ASND) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/ASND/earnings
Underlying data: Yahoo Finance.